Welcome to our dedicated page for Neuraxis SEC filings (Ticker: NRXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NeurAxis, Inc. (NRXS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. NeurAxis is a medical technology company focused on neuromodulation therapies, including its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology and IB-Stim device for functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD), and FD-related nausea symptoms in patients 8 years and older.
Through this page, users can review current and historical reports such as Form 8-K filings, which NeurAxis uses to announce material events. Recent 8-Ks describe FDA 510(k) clearance for expanded PENFS indications in patients aged 8 years and older, including adults, and outline the significance of this clearance as the first FDA clearance or approval for a treatment specifically addressing functional dyspepsia in the adult patient population. Other 8-Ks detail capital markets activity, including an At The Market Offering Agreement under a shelf registration statement on Form S-3, preliminary financial estimates, and the termination of a license and collaboration agreement related to the NSS-2 Bridge device.
Investors can also use this filings page to monitor financing structures and equity programs, such as updates to the at-the-market offering capacity and the adoption of the NeurAxis, Inc. 2025 Employee Stock Purchase Plan. These documents explain how the company may issue common stock, the role of its sales agent, applicable commissions, and share limits under employee purchase arrangements.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the implications of new 8-Ks, registration statements, and related exhibits. Real-time updates from EDGAR ensure that new NeurAxis filings appear promptly, while structured access to exhibits, legal opinions, and financial disclosures supports deeper analysis of the company’s regulatory, financing, and operational developments.
Neuraxis, Inc. (NRXS) reporting person Timothy Robert Henrichs received restricted stock unit (RSU) awards as compensation and hiring/bonus grants totaling 242,017 RSUs across four grants. The reported grant dates are 01/03/2025, 03/04/2025 and 03/18/2025. Each grant is described as vesting in full at the end of 36 months. The awards convert into an equal number of common shares upon vesting: 8,037; 100,000; 66,000; and 67,980 shares respectively. The Form 4 lists per-share figures of $2.43 for the 03/18/2025 and 01/03/2025 grants and $2.18 for the 03/04/2025 grant, and indicates these RSUs were granted as compensation for services as an independent director, a hiring grant, a bonus, and under the Long-Term Incentive Plan. The filing is signed by the reporting person on 09/10/2025.
Neuraxis, Inc. (NRXS) director Jane Elizabeth Keyser received 13,157 shares of common stock as compensation for board service. The transaction was executed on 01/17/2025 at a reported price of $2.85 per share, leaving the reporting person with 24,737 shares beneficially owned following the issuance. The Form 4 identifies Keyser as a director and the shares were issued specifically as independent director compensation. The filing is signed by Beth Keyser on 09/10/2025 and includes the reporting person’s address in Carmel, Indiana.
Neuraxis, Inc. reported a Form 4 showing that Adrian Miranda, CMO and SVP Science & Tech, was granted restricted stock units (RSUs) totaling 75,000 underlying shares in three separate awards. The grants are identified as 10,000, 30,000 and 35,000 RSUs and show per-share prices of $2.18 for two awards and $2.42 for one award. The filing states each RSU award will vest in full after 36 months. The reporting person is a company officer and the Form 4 was signed by Adrian Miranda.
Neuraxis, Inc. (NRXS) reported an insider equity grant to director Bradley M. Watkins. On 01/17/2025 Mr. Watkins was issued 13,157 shares of common stock as compensation for his services as an independent director at an effective price of $2.85 per share. After the issuance he beneficially owned 24,737 shares in a direct ownership form. The Form 4 was signed by Mr. Watkins on 09/10/2025. This filing records a routine director compensation equity award and does not include derivative transactions.
Thomas Joeseph Carrico, an officer of Neuraxis, Inc. (NRXS), received three awards of restricted stock units (RSUs) totaling 72,435 shares across transaction dates of 01/03/2025 and 03/04/2025. The grants are recorded as non‑derivative/derivative entries converting to common stock at reported per‑share values of $2.18 and $2.42 depending on the grant.
The RSUs are described as bonus and long‑term incentive awards under the company’s equity plans and will vest in full at the end of 36 months, meaning Carrico will obtain the underlying common shares only after the three‑year vesting period. The filing shows the awards are held directly by the reporting person.
Neuraxis, Inc. has entered into an At-The-Market (ATM) Offering Agreement with Craig-Hallum Capital Group LLC that allows the company to offer and sell shares of its common stock, at the company's discretion, through the sales agent. The agreement permits aggregate sales with an offering price up to $3,300,000. The arrangement gives Neuraxis a standing mechanism to raise capital by selling shares into the market over time rather than through a single underwritten offering.
This filing discloses the existence and terms of the sales-agent relationship and the maximum aggregate offering amount; no specific sales, pricing, or use-of-proceeds details are included in the provided text.
Neuraxis, Inc. is launching an at-the-market stock offering of up to $3,300,000 in common shares through Craig-Hallum Capital Group. The shares may be sold from time to time on the NYSE American or other U.S. trading markets at prevailing prices, with Craig-Hallum acting as sales agent or principal and earning a 3.0% commission on gross proceeds.
As of August 27, 2025, Neuraxis had 9,872,776 common shares outstanding, and assumes a reference price of $2.42 per share, the last reported sale price, for illustrative calculations. If the full amount is sold at that price, the company estimates its net tangible book value per share would rise from $0.40 to $0.62, implying dilution of $1.80 per share to new investors. Net proceeds are intended for capital expenditures, sales and marketing, and general working capital, with management retaining broad discretion over how the funds are allocated.
NeurAxis, Inc. reported quarterly net sales of $894,086, an increase of 46.2% versus the prior-year quarter, and six‑month net sales of $1.79 million. Cash rose by $2,291,586 to $5,988,456 at June 30, 2025, driven largely by proceeds of $4,999,999 from a May 22, 2025 common stock offering (1,538,461 shares issued) and $1,002,991 from warrant exercises.
Despite revenue growth and improved liquidity, the company reported a six‑month net loss of $3,969,102 and an accumulated deficit of $60,768,714. Management and auditors disclosed substantial doubt about the company’s ability to continue as a going concern. The company accrued a $375,000 current liability and $267,540 noncurrent liability for a tentative $750,000 litigation settlement. Series B Preferred Stock outstanding totaled 3,896,907 shares and common shares outstanding were 9,858,716 as of June 30, 2025.
FAQ
What is the current stock price of Neuraxis (NRXS)?
What is the market cap of Neuraxis (NRXS)?
